#USA #New York #Class Action #Securities #Tenax Therapeutics

Tenax Therapeutics Investors Alert: Upcoming Class Action Suit Deadline

Investors in Tenax Therapeutics, Inc. (NASDAQ: TENX) have been alerted by SueWallSt regarding an important securities class action lawsuit deadline, set for December 28, 2026. This announcement comes after a significant drop in the company's stock price, which plunged by nearly 90% in a single trading session. The lawsuit focuses on allegations that Tenax management misrepresented key elements related to TNX-103, especially concerning its regulatory approval pathway and commercial prospects.

Context of the Allegations

The class period for the lawsuit spans from November 13, 2023, to August 7, 2026. According to the complaint, Tenax Therapeutics may have falsely assured investors that the pathway for getting TNX-103 approved would be more straightforward, particularly highlighting a six-minute walk endpoint as a potential method for approval. However, the company's Phase 3 LEVEL trial did not meet the primary endpoint, contrary to management's previous claims. This instance of alleged miscommunication has left many investors in the lurch, facing significant losses.

The Financial Implications

Following these misleading statements from management, Tenax shares fell drastically—from around $134 million raised from various offerings and private placements to a staggering decrease when the trial results were publicly shared. Legal expert Joseph E. Levi commented, "Investors deserve transparency about material risks that could affect their investments, particularly with a company still in development."

Misleading Statements and Their Consequences

At the November 13, 2024, Guggenheim Healthcare Innovation Conference, Tenax's management indicated they believed they were on a solid path to gain approval based on quickly obtainable metrics. They indicated optimism about their potential gains in the market, aiming to make TNX-103 the first approved treatment for pulmonary hypertension with preserved ejection fraction (PH-HFpEF).

However, when the trial results began to roll in, initial excitement transformed into dismay as it became clear that the promising claims didn’t hold up to rigorous clinical scrutiny. The LEVEL study failed to meet its primary endpoint, further exacerbating the concerns surrounding the company's disclosure practices.

Legal Recourse for Investors

The legal action is currently filed in the United States District Court for the Middle District of North Carolina. For tenacious investors holding shares during the class period, now is the time to review brokerage records and prepare documentation if seeking to recover investment losses. Joe Levi and his team are offering a free assessment to help navigate this complex situation. Importantly, those who have sold their shares may still have eligibility based on their purchase dates.

Future Steps for Investors

If you have been impacted by your investment in Tenax Therapeutics, it is vital to take action before the deadline. Investors can reach out to the law firm Levi Korsinsky LLP for a no-obligation review of their potential claims. The firm has a solid reputation for representing aggrieved shareholders and recovering significant amounts in past securities litigation cases.

The impending deadline for applying for lead plaintiff status emphasizes the need for affected shareholders to be proactive. The class action suit is not just a legal formality; it represents a crucial attempt to hold corporations accountable for their statements and promises made to shareholders.

In conclusion, while Tenax Therapeutics faces serious challenges, investors now have an opportunity to reclaim losses through legal channels. It is essential to stay informed and act quickly to ensure that their rights are protected in this turbulent market landscape.